NHS England said that, according to trial data, palivizumab provides around 55% protection while nirsevimab offers more than 80% protection against the virus. RSV infects 90% of children by the age of two and is one of the leading causes of hospital admission, noted NHS England. Loading…Alternatively, their family will be directed by the clinical team managing their child’s health on how to receive the immunisation ahead of winter, said NHS England. Dr Claire Fuller, co-national medical director for NHS England said: “This injection will provide premature babies with a protective bubble against RSV just in time for the colder months. The injection, which was recommended by the Joint Committee on Vaccination and Immunisation, follows the first-ever launch of an RSV vaccine (Abrysvo) for pregnant women last September.
